Post stroke hemiplegia: Interest of botulinum toxin injection at the upper limb;Hémiplégie vasculaire: Intérêt de l'injection de toxine botulique au membre supérieur

Annales de Readaptation et de Medecine Physique

Volumn 46, Issue 6, 2003, Pages 286-295

  Rousseaux, M ^a   Launay, M J ^a   Kozlowski, O ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Botulinum toxin; Comfort; Hand function; Spasticity; Upper limb

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A;

CAREGIVER; FUNCTION TEST; FUNCTIONAL ASSESSMENT; HEMIPLEGIA; HUMAN; MEDLINE; PATIENT SATISFACTION; RATING SCALE; REVIEW; SPASTICITY; STROKE;

EID: 0042429211     PISSN: 01686054     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-6054(03)00112-0     Document Type: Article

References (57)

1. Albany K. Physical and occupational therapy considerations in adult patients receiving botulinum toxin injections for spasticity. Muscle Nerve 1997;6(suppl):S221-31.
2. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-6.
3. Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001;8:559-65.
4. Bakheit AM, Sawyer J. The effects of botulinum toxin treatment on associated reactions of the upper limb on hemiplegic gait-a pilot study. Disabil Rehabil 2002;24:519-22.
5. Bhakta BB, Bamford JM, Cozens J, Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996;61:30-5.
6. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-21.
7. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Quantifying associated reactions in the paretic arm in stroke and their relationship to spasticity. Clin Rehabil 2001;15(1):95-206.
8. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-7.
9. Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante R. Botulinum toxin A for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 1990;12:392-8.
10. Borodic GE, Ferrante R. Effects of repeating botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 1992;12:121-7.
11. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996;46:26-9.
12. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400.
13. Brashear A, Zafonte R, Corcoran M, Galvez-Jimenez N, Gracies JM, Gordon MF, et al. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002;83:1349-54.
14. Cobb DB, Watson WA, Fernandez MC. Botulism-like syndrome after injections of botulinum toxin. Vet Hum Toxicol 2000;42:163.
15. Das TK, Park DM. Botulinum toxin in treating spasticity. Br J Clin Pract 1989;43:401-3.
16. Das TK, Park DM. Effects of treatment with botulinum toxin on spasticity. Postgrad Med J 1989;65:208-10.
17. De Souza LH, Langton Hewer R, Miller S. Assessment of recovery of arm control in hemiplegic stroke patients. Arm function test. Int Rehabil Med 1980;2:3-9.
18. Dunne JW, Heye N, Dunne SL. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 1995;58:232-5.
19. Eleopra R, Tugnoli V, Caniatti N, De Grandis D. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996;46:1158-60.
20. Friedman A, Diamond M, Johnston MV, Daffner C. Effect of botulinum toxin A on upper limb spasticity in children with cerebral palsy. Am J Phys Med Rehabil 2000;79:53-9.
21. Girlanda P, Quartarone A, Sinicropi S, Nicolosi T, Roberto ML, Picciolo G, et al. Botulinum toxin in upper limb spasticity: study of reciprocal inhibition between forearm muscles. Neuroreport 1997;29:3039-44.
22. Gowland C, Debruins H, Basmajian JV. Agonist and antagonist activity during volontary upper-limb movement in patients with stroke. Phys Ther 1992;72:624-33.
23. Gracies JM, Weisz DJ, Yang BY, Flanagan S, Simpson D. Effects of botulinum toxin type A dilution and endplate targeting technique in upper limb spasticity. Poster presented at the 127th Annual Meeting of the American Neurological Association. New York. october 13-16, 2002.
24. Grazko MA, Polo K, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995;45:712-7.
25. Hamilton BB, Granger CV, Sherwin FS, Zielezny M, Tashman JS. A uniform national data system for medical rehabilitation. In: Fuhrer MJ, editor. Rehabilitation outcomes: analysis and measurment. Baltimore, MD: Brooks; 1987.
26. Hesse S, Friedrich H, Domasch C, Mauritz KH. Botulinum toxin therapy for upper limb flexor spasticity: preliminary results. J Rehabil Sci 1992;5:98-101.
27. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke. A randomized, double-blind, placebo-controlled trial. Clin Rehabil 1998;12:381-8.
28. Konstanzer A, Ceballos-Baumann AO, Dressnandt J, Conrad B. Lokale Injektionsbehandlung mit botulinum toxin A bei schwerer Arm-und Beinspastik. Nervenarzt 1993;64:517-23.
29. Lagalla G, Danni M, Reiter F, Ceravolo MG, Provinciali L. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil 2000;79:377-84.
30. Lincoln N, Leadbitter D. Assessment of motor function in stroke patients. Physiotherapy 1979;65:48-51.
31. Mahoney FI, Barthel DW. Functional evaluation: Barthel index. Md State Med J 1965;14:61-5.
32. Mathiowetz V, Weber K, Kashman N, Volland G. Adult norms for the nine-hole peg test of finger dexterity. Occup Ther J Res 1985;5:24-37.
33. Mémin B, Pollak P, Hommel M, Perret J. Effets de la toxine botulinique sur la spasticité. Rev Neurol (Paris) 1992;148:212-4.
34. Mezaki T, Kaji R, Kohara N, Kimura J. Development of general weakness in a patient with amytrophic lateral sclerosis after focal botulinum toxin injection. Neurology 1996;46:845-6.
35. Palmer DT, Horn LJ, Harmon RL. Botulinum toxin treatment of lumbrical spasticity, a brief report. Am J Phys Med Rehabil 1998;77:348-50.
36. Pandyan AD, Vuadens P, van Wijck FM, Stark S, Johnson GR, Barnes MP. Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population. Clin Rehabil 2002;16:654-60.
37. Panizza M, Castagna M, di Summa A, Saibene L, Grioni G, Nilsson J. Functional and clinical changes in upper limb spastic patients treated with botulinum toxin (BTX). Funct Neurol 2000;15:147-55.
38. Pierson SH, Katz DI, Tarsy D. Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Arch Phys Med Rehabil 1996;77:717-21.
39. Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol 1996;53:617-24.
40. Reiter F, Danni M, Ceravolo MG, Provinciali L. Disability changes after treatment of upper limb spasticity with botulinum toxin. J Neuro Rehab 1996;10:47-52.
41. Richardson D, Sheean G, Werring D, Desai M, Edwards S, Greenwood R, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000;69:499-506.
42. Rodriquez AA, Mc Ginn M, Chappell R. Botulinum toxin injection of spastic finger flexors in hemiplegic patients. Am J Phys Med Rehabil 2000;79:44-7.
43. Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol 2002;249:76-84.
44. Rousseaux M, Kozlowski O, Launay MJ. Toxine botulique et préhension dans l'hémiplégie vasculaire. In: Pélissier J, Bénaïm C, Enjalbert M, editors. Préhension et hémiplégie vasculaire. Paris: Masson; 2002. p. 108-18.
45. Rousseaux M, Delattre S, Kozlowski O, Perennou D. Prise en charge du confort du patient au stade évolué. In: Pélissier J, Labauge P, Joseph PA, editors. Rééducation et réadaptation de la sclérose en plaques. Paris: Masson; 2003.
46. Sampaio C, Ferreira JJ, Pinto AA, Crespo M, Ferro JM, Castro-Caldas A. Botulinum toxin type A for the treatment of arm and hand spaticity in stroke patients. Clin Rehabil 1997;11:3-7.
47. Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol 2001;14:771-6.
48. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized double-blind, placebo-controlled trial. Neurology 1996;46:1306-10.
49. Smith SJ, Ellis E, White S, Moere AP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000;14:5-13.
50. Tuite PJ, Lang AE. Severe and prolonged dysphagia complicating botulinum toxin A injections for dystonia in Machado-Joseph disease. Neurology 1996;46:846.
51. van Kuijk AA, Geurts AC, Bevaart BJ, van Limbeek J. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature. J Rehabil Med 2002;34:51-61.
52. Viriyavejakul A, Vachalathiti R, Poungvarin N. Botulinum treatment for post-stroke spasticity: low dose regime. J Med Assoc Thai 1998;81:413-22.
53. Wang HC, Hsieh LF, Chi WC, Lou SM. Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil 2002;81:272-8.
54. Watanabe Y, Bakheit AM, McLellan DL. A study of the effectiveness of botulinum toxin type A (Dysport) in the management of muscle spasticity. Disabil Rehabil 1998;20:62-5.
55. Wissel J, Muller J, Heinen F, Mall V, Sojer M, Ebersbach G, et al. Sicherheit und Verträglichkeit einer einmaligen Botulinum Toxin Typ A-Behandlung bei 204 Patienten mit Spastizität und lokalen assoziierten Störungen. Wien Klin Wochenschr 1999;111:837-42.
56. Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000;20:44-9.
57. Zuber M, Sebald M, Bathien N, De Recondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance. Neurology 1993;43:1715-8.